We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.51 | 3.02 | 4.00 | 202,000 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
TIDMPRM
RNS Number : 4665D
Proteome Sciences PLC
09 October 2018
9 October 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 9 October 2018 that on the 5 and 8 October 2018 it purchased 54,000 and 460,899 Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 60,851,987 equivalent to 20.62% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 60,851,987 Ordinary Shares of the Company representing 20.62% of the issued share capital of the Company.
The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person closely associated a) Name: Martin Diggle ----------------------------------------- -------------------------------- Reason for the notification --------------------------------------------------------------------------- a) Position/status: Non-Executive Director ----------------------------------------- -------------------------------- b) Initial notification/Amendment: Initial Notification ----------------------------------------- -------------------------------- Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --------------------------------------------------------------------------- a) Name: Proteome Sciences Plc ----------------------------------------- -------------------------------- b) LEI: 213800Q62ICXANKU2986 ----------------------------------------- -------------------------------- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------------- a) Description of the financial instrument, Ordinary Shares of 1p nominal type of instrument: value Identification code: GB0003104196 ----------------------------------------- -------------------------------- b) Nature of the transaction: Purchase of Ordinary Shares ----------------------------------------- -------------------------------- c) Price(s) and volume(s): Price(s) Volume(s) 3.60 514,899 ---------- ----------------------------------------- -------------------------------- d) Aggregated information: Single transaction as in * Aggregated volume: 4 c) above Average Volume(s) Price 3.60 54,000 * Price: ---------- 3.60 460,899 ---------- ----------------------------------------- -------------------------------- e) Date of the transaction: 5 October 2018 and 8 October 2018 respectively ----------------------------------------- -------------------------------- f) Place of the transaction: London Stock Exchange, AIM (XLON) ----------------------------------------- --------------------------------
For further information:
Proteome Sciences plc Dr Jeremy Haigh, Chief Executive Tel: +44 (0)20 7043 2116 Officer Dr Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer finnCap Limited (Nominated Adviser & Broker) Geoff Nash/Hannah Boros (Corporate Tel: +44 (0)20 7220 0500 Finance) Tim Redfern (Broking)
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) ) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator(TM) ). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHFSIFLUFASEES
(END) Dow Jones Newswires
October 09, 2018 10:28 ET (14:28 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions